United Kingdom

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting

Lead Product(s): FS222

Therapeutic Area: Oncology Product Name: FS222

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

FS222 targets PD-L1 (programmed death-ligand 1), the immune checkpoint protein which regulates the balance of activated T cells in the immune system and CD137, a co-stimulatory molecule from the tumor necrosis factor receptor superfamily (TNFRSF).

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor A...

Lead Product(s): KTX-201

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

The company will present preclinical data demonstrating that its STAT3 degraders downregulated immune checkpoint signals on tumor cells and positively modulated composition and activity of immune cells in the TME.

Almac Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301

Lead Product(s): ALM301

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 14, 2020

Details:

The agreement aims at advancing the development and commercialisation of Almac's portfolio projects – ALM301. The molecule is currently in late-stage pre-clinical development, and the partner will complete this before progressing into the clinical development phase.

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research

Lead Product(s): FS222

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

Preclinical data show synergistic benefit of F-star’s tetravalent mAb² with evidence of robust CD4+ and CD8+ T cell activation which surpassed combinations of monoclonal antibodies in in-vitro assays.